December 19, 2025 | Princeton, New Jersey — Bristol Myers Squibb announced a landmark agreement with the U.S. government aimed at improving affordability and access to critical medicines for Americans, anchored by making Eliquis® (apixaban) available free of charge to the Medicaid program beginning January 1, 2026. The agreement also includes a commitment to donate more than seven tons of Eliquis active pharmaceutical ingredient (API) to support U.S. supply chain resilience, alongside three years of tariff relief for the company.
Science Significance
From a scientific and pharmaceutical standpoint, the agreement centers on Eliquis®, the most widely prescribed oral anticoagulant in the United States, used to reduce the risk of stroke and blood clots in patients with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Ensuring uninterrupted access to this medicine is critical, as consistent anticoagulation therapy directly correlates with reduced morbidity, mortality, and hospitalization rates. The API donation underscores the importance of robust manufacturing science, quality control, and GMP-compliant production to maintain continuous availability of a life-saving therapy relied upon by millions of patients daily.
Regulatory Significance
Regulatorily, the agreement represents a post-approval lifecycle commitment that intersects with FDA oversight, GMP manufacturing, pharmacovigilance, and supply chain governance. By contributing to the U.S. Strategic Active Ingredient Reserve, Bristol Myers Squibb reinforces regulatory objectives focused on drug security, traceability, and continuity of supply. The arrangement also reflects a collaborative regulatory approach in which access, quality, and safety obligations are balanced with incentives such as temporary tariff relief, highlighting evolving frameworks for managing essential medicines in the U.S.
Business Significance
Advertisement
For Bristol Myers Squibb, the agreement aligns with its broader strategy to invest $40 billion in the United States over the next five years, including expanded domestic manufacturing and onshoring of medicines. While Eliquis will be provided to Medicaid at no cost, the company gains pricing stability, tariff relief, and policy certainty over a defined three-year period. The agreement also supports direct-to-patient access models for several additional medicines at significant discounts, demonstrating how business sustainability and public health goals can converge through structured public–private collaboration.
Patients’ Significance
The patient impact is substantial. Making Eliquis available free to Medicaid beneficiaries directly benefits millions of vulnerable Americans who depend on anticoagulation therapy to prevent life-threatening events such as stroke and pulmonary embolism. Reduced cost barriers improve medication adherence, which is essential for chronic cardiovascular conditions. Beyond Eliquis, expanded discounted access to other critical medicines further enhances equitable treatment access, particularly for patients who are uninsured or pay out of pocket.
Policy Significance
At a policy level, the agreement signals a new model for government–pharma engagement focused on affordability, access, and domestic resilience without imposing blanket pricing mandates. By coupling API stockpiling, Medicaid access, and domestic investment with tariff relief, policymakers advance objectives related to national drug security, healthcare cost containment, and innovation preservation. The confidentiality of specific terms reflects the complexity of balancing market dynamics with public interest, setting a precedent for future negotiations involving essential medicines.
The agreement between Bristol Myers Squibb and the U.S. government represents a significant step in redefining how critical medicines are priced, supplied, and accessed in the United States. By ensuring free Medicaid access to Eliquis®, strengthening API reserves, and expanding domestic production, the initiative reinforces the role of cGxP-compliant manufacturing and regulatory collaboration in safeguarding public health. For cGxP.wire readers, the announcement highlights how policy-driven pharmaceutical strategies can deliver measurable patient benefit while maintaining the integrity of regulated drug development and supply systems.
Source: Bristol Myers Squibb press release
